Wall Street Zen Upgrades Teleflex (NYSE:TFX) to “Hold”

Teleflex (NYSE:TFX) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

A number of other research firms have also weighed in on TFX. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a research report on Friday, March 27th. Needham & Company LLC lifted their price target on Teleflex from $138.00 to $147.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Wells Fargo & Company lifted their price target on Teleflex from $116.00 to $130.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Raymond James Financial raised Teleflex from a “market perform” rating to an “outperform” rating and set a $128.00 price target on the stock in a research note on Friday, March 27th. Finally, Bank of America raised Teleflex from an “underperform” rating to a “neutral” rating and set a $135.00 price target on the stock in a research note on Monday, April 13th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $138.50.

Teleflex Trading Up 0.2%

Shares of TFX stock opened at $136.86 on Friday. The stock has a 50-day simple moving average of $116.87 and a 200 day simple moving average of $116.43. Teleflex has a fifty-two week low of $100.18 and a fifty-two week high of $139.67. The stock has a market capitalization of $6.06 billion, a P/E ratio of -6.66, a P/E/G ratio of 0.98 and a beta of 0.84. The company has a quick ratio of 2.01, a current ratio of 2.54 and a debt-to-equity ratio of 0.81.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share for the quarter, missing the consensus estimate of $3.73 by ($1.80). Teleflex had a negative net margin of 30.56% and a positive return on equity of 14.30%. The firm had revenue of $569.00 million for the quarter, compared to the consensus estimate of $912.57 million. During the same period in the prior year, the business earned $3.89 EPS. The company’s quarterly revenue was down 28.5% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. On average, sell-side analysts expect that Teleflex will post 6.77 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Teleflex

A number of institutional investors have recently bought and sold shares of TFX. MassMutual Private Wealth & Trust FSB boosted its position in Teleflex by 57.9% during the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 210 shares of the medical technology company’s stock worth $26,000 after acquiring an additional 77 shares during the period. Banque Cantonale Vaudoise increased its holdings in shares of Teleflex by 82.5% in the 4th quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 113 shares during the period. Hantz Financial Services Inc. increased its holdings in shares of Teleflex by 248.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 279 shares of the medical technology company’s stock valued at $34,000 after purchasing an additional 199 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Teleflex in the 3rd quarter valued at about $35,000. Finally, V Square Quantitative Management LLC acquired a new position in shares of Teleflex in the 4th quarter valued at about $37,000. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.